Refine
Has Fulltext
- yes (19)
Is part of the Bibliography
- yes (19)
Year of publication
Document Type
- Journal article (19)
Language
- English (19)
Keywords
- CXCR4 (8)
- PET (7)
- theranostics (6)
- PRRT (4)
- chemokine receptor (3)
- molecular imaging (3)
- multiple myeloma (3)
- DOTATOC (2)
- NET (2)
- PET/CT (2)
- SSTR (2)
- fibroblast activation protein (2)
- medicine (2)
- radionuclide therapy (2)
- sarcoidosis (2)
- somatostatin receptor (2)
- 11C-Methionine PET/CT (1)
- 18F-FDG PET/CT (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- Arginine (1)
- C-X-C motif chemokine receptor 4 (1)
- CXCR4/SDF-1 (1)
- DOTA-EB-TATE (1)
- FDG (1)
- FDG PET/CT (1)
- Hyperkalaemia (1)
- Lysine (1)
- MAG3 (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- Somatostatin receptor expression (1)
- [177Lu]/[90Y]PentixaTher (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- agreement (1)
- amino acids (1)
- androgen deprivation therapy (1)
- autologous transplantation (1)
- biokinetics (1)
- biomarker (1)
- bone disease (1)
- cancer (1)
- cells (1)
- comparability (1)
- detection rate (1)
- endoradiotherapy (1)
- evans blue (1)
- head and neck cancer (1)
- hyperkalemia (1)
- in vivo imaging (1)
- intraindividual comparison (1)
- involvement (1)
- kidney function (1)
- malignancies (1)
- metabolic tumour volume (MTV) (1)
- microenvironment (1)
- neuroendocrine tumor (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- pleural mesothelioma (1)
- positron emission tomography (1)
- prostate-specific membrane antigen (PSMA) (1)
- radioligand therapy (1)
- recurrent prostate cancer (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin receptors (1)
- survival (1)
- total lesion PSMA (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (19)
- Medizinische Klinik und Poliklinik II (6)
- Pathologisches Institut (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Medizinische Klinik und Poliklinik I (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Urologische Klinik und Poliklinik (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Background
CXCR4-directed positron emission tomography/computed tomography (PET/CT) has been used as a diagnostic tool in patients with solid tumors. We aimed to determine a potential correlation between tumor burden and radiotracer accumulation in normal organs.
Methods
Ninety patients with histologically proven solid cancers underwent CXCR4-targeted [\(^{68}\)Ga]Ga-PentixaFor PET/CT. Volumes of interest (VOIs) were placed in normal organs (heart, liver, spleen, bone marrow, and kidneys) and tumor lesions. Mean standardized uptake values (SUV\(_{mean}\)) for normal organs were determined. For CXCR4-positive tumor burden, maximum SUV (SUV\(_{max}\)), tumor volume (TV), and fractional tumor activity (FTA, defined as SUV\(_{mean}\) x TV), were calculated. We used a Spearman's rank correlation coefficient (ρ) to derive correlative indices between normal organ uptake and tumor burden.
Results
Median SUV\(_{mean}\) in unaffected organs was 5.2 for the spleen (range, 2.44 – 10.55), 3.27 for the kidneys (range, 1.52 – 17.4), followed by bone marrow (1.76, range, 0.84 – 3.98), heart (1.66, range, 0.88 – 2.89), and liver (1.28, range, 0.73 – 2.45). No significant correlation between SUV\(_{max}\) in tumor lesions (ρ ≤ 0.189, P ≥ 0.07), TV (ρ ≥ -0.204, P ≥ 0.06) or FTA (ρ ≥ -0.142, P ≥ 0.18) with the investigated organs was found.
Conclusions
In patients with solid tumors imaged with [\(^{68}\)Ga]Ga-PentixaFor PET/CT, no relevant tumor sink effect was noted. This observation may be of relevance for therapies with radioactive and non-radioactive CXCR4-directed drugs, as with increasing tumor burden, the dose to normal organs may remain unchanged.